



UNIVERSITY  
OF WOLLONGONG  
AUSTRALIA

University of Wollongong  
Research Online

---

Faculty of Science, Medicine and Health - Papers

Faculty of Science, Medicine and Health

---

2016

# Why are fish oil supplements apparently failing to reproduce fish consumption epidemiology in RCT for cardiovascular disease?

Peter L. McLennan

*University of Wollongong*, [petermcl@uow.edu.au](mailto:petermcl@uow.edu.au)

Gregory E. Peoples

*University of Wollongong*, [peoples@uow.edu.au](mailto:peoples@uow.edu.au)

Michael Macartney

*University of Wollongong*, [mm584@uowmail.edu.au](mailto:mm584@uowmail.edu.au)

S K. Venoe

*Aalborg University*

---

## Publication Details

McLennan, P., Peoples, G. E., Macartney, M. J. & Venoe, S. (2016). Why are fish oil supplements apparently failing to reproduce fish consumption epidemiology in RCT for cardiovascular disease?. In The Nutrition Society of Australia and New Zealand 2015 Annual Scientific Meeting, 1-4 Dec 2015, Wellington, New Zealand. *Journal of Nutrition & Intermediary Metabolism*, 4 7-7.

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:  
[research-pubs@uow.edu.au](mailto:research-pubs@uow.edu.au)

---

# Why are fish oil supplements apparently failing to reproduce fish consumption epidemiology in RCT for cardiovascular disease?

## **Abstract**

Abstract of a presentation.

## **Publication Details**

McLennan, P., Peoples, G. E., Macartney, M. J. & Venoe, S. (2016). Why are fish oil supplements apparently failing to reproduce fish consumption epidemiology in RCT for cardiovascular disease?. In The Nutrition Society of Australia and New Zealand 2015 Annual Scientific Meeting, 1-4 Dec 2015, Wellington, New Zealand. *Journal of Nutrition & Intermediary Metabolism*, 4 7-7.

## A DOSE-RESPONSE TRIAL OF LACTOFERRIN INTERVENTION ON GENE EXPRESSION PROFILE IN POSTNATAL PIGLETS

Y. Chen<sup>1</sup>, Y. Shi<sup>2</sup>, F.A. Troy, II<sup>3</sup>, B. Wang<sup>4</sup>. <sup>1</sup>School of Medicine, Xiamen University, Fujian, China; <sup>2</sup>Nestle Research Centre, Beijing, China; <sup>3</sup>Dept. of Biochemistry & Molecular Medicine, Uni. of California School of Medicine, Davis, USA; <sup>4</sup>EH Graham Centre for Agricultural Innovation, Charles Sturt Uni., Wagga Wagga, NSW, Australia  
E-mail address: [biwang@csu.edu.au](mailto:biwang@csu.edu.au) (B. Wang)

**Background/Aims:** The aim of this study was to investigate the dose-response effect of lactoferrin (Lf) intervention on gene expression in the hippocampus of postnatal piglets during neurodevelopment.

**Methods:** Fifty-one 3-day-old piglets were randomly allocated into a high (H) Lf dose group ( $n = 18$ ), a low (L) Lf dose group ( $n = 17$ ) and a control (C) group ( $n = 16$ ). Piglets were fed sow milk replacer supplemented with Lf at 285 mg/kg/d (H), 155 mg/kg/d (L) and 16 mg/kg/day (C). Piglets were euthanized at 38 days of age. RNA transcript profiling in the hippocampus was carried out using RNA isolated from 10 piglets/gp on Porcine Affymetrix. A TaqMan<sup>®</sup> Gene expression assay based on qPCR was used to validate the microarray findings. The results were analyzed using the Partek Genomics Suite 6.5 software and Ingenuity System.

**Results:** Low-dose Lf activated neurotrophin signalling pathways and modulated expression of genes associated with neurodevelopment, learning & memory, including *BDNF*, *FGFR*, *IRS1* and *CAMKK1*. Functional analysis showed network signalling impacted brain development, neuron structure and long-term potentiation. In contrast, piglets on the high dose of Lf showed no effect on neurotrophin signalling but an increase in gene expression and signalling pathways leading to cell death/apoptosis and decreased neurogenesis.

**Conclusions:** Low-dose Lf supplementation up-regulated neurotrophin signalling pathways associated with neurodevelopment and cognition, a finding in contrast to piglets on a high dose of Lf. The molecular mechanism(s) underlying this paradoxical finding remains under study.

**Funding source(s):** Medical School, Xiamen University & Nestle Research Centre, Beijing.

## CONCURRENT SESSION 2: LIPIDS. POSTPRANDIAL TRIGLYCERIDES RESPONSE TO KRILL OIL SUPPLEMENTATION IN HEALTHY WOMEN

H. Sung<sup>1</sup>, A. Sinclair<sup>2</sup>, P. Lewandowski<sup>2</sup>, X. Su<sup>1</sup>. <sup>1</sup>College of Health and Biomedicine, Victoria University, Melbourne, Australia; <sup>2</sup>School of Medicine, Deakin University, Victoria, Australia  
E-mail address: [teetree86@gmail.com](mailto:teetree86@gmail.com) (H. Sung)

**Background:** Krill oil (KO) has been suggested to have higher bioavailability of EPA and DHA compared with fish oil. There are limited reports on the postprandial effects of KO. This study investigates the impacts of supplementation with KO and fish oil (FO) on plasma lipid profiles in the postprandial state.

**Methods:** This is a randomised cross-over study. Test meals consisting fresh mashed-potato and 15 g of olive oil (OO) and 5 g of with three oil supplements (KO, FO or OO) were randomly provided on each study day with seven days wash-out period between. Blood samples were collected at the baseline and post consumption of test meal/supplement on hourly basis for 5 hours. Postprandial changes were assessed using SPSS. SPANOVA for repeated measure was performed to assess the changes between the treatments. One-way ANOVA and multiple comparisons using Tukey HSD post-hoc analysis were also performed to assess the changes in the parameters over time within the treatment group.  $P < 0.05$  was considered statistically different.

**Results:** There were no significant changes in the postprandial TAG levels in either chylomicron or plasma between the three oil treatments ( $p = 0.783$ ). However within the treatment groups, changes in TAG with time after oil consumption were significantly different ( $p < 0.001$ ) and the magnitude of changes varies in each treatment.

**Conclusions:** There were no significant difference in the absorption of TAG in chylomicron or plasma between FO and KO. Since KO contains *n-3* fatty acids in phospholipids, *n-3* profile in postprandial plasma phospholipid

should be examined.

**Funding source(s):** College of Health and Biomedicine, Victoria University, Melbourne, Australia.

## WHY ARE FISH OIL SUPPLEMENTS APPARENTLY FAILING TO REPRODUCE FISH CONSUMPTION EPIDEMIOLOGY IN RCT FOR CARDIOVASCULAR DISEASE?

P. McLennan<sup>1</sup>, G.E. Peoples<sup>1</sup>, M.J. Macartney<sup>1</sup>, S.K. Venoe<sup>2</sup>. <sup>1</sup>Graduate School of Medicine, University of Wollongong, NSW, Australia; <sup>2</sup>Faculty of Medicine, Aalborg University, Aalborg, Denmark  
E-mail address: [petermcl@uow.edu.au](mailto:petermcl@uow.edu.au) (P. McLennan)

**Background/Aims:** Regular fish consumption is associated with low cardiovascular disease risk. However, randomised control trials (RCT) of fish oil supplements produce variable results, recently interpreted to no longer support beneficial effects of long chain *n-3* polyunsaturated fatty acids (LCn-3PUFA) EPA and DHA in treating or preventing cardiovascular disease.

**Methods:** This review considers issues key to understanding the contradiction.

**Results:** 1) Most RCT report no exclusion criteria for fish eaters and fewer analyse *n-3* PUFA status. Even in RCT with exclusions overlap of tissue *n-3* PUFA status remain between control and treated groups. 2) Cardiac effects (sudden death, heart failure) derive from myocardial membrane incorporation of DHA. The LCn-3PUFA intake in cohort studies derives from seafood, providing more DHA than EPA, whereas most RCT use supplements rich in EPA, low in DHA. 3) Nutritional and therapeutic effects of LCn-3PUFA derive from direct and indirect mechanisms. Effects on heart rate, heart failure and sudden death occur at lower intakes than influence classical coronary artery disease risk factors such as hypertriglyceridaemia. RCT designs combining cardiac and arterial disease populations and composite endpoints propose a common substrate and assume common mechanisms of action.

**Conclusions:** Many fish oil RCT included in systematic reviews are methodologically unsound, failing to consider background diet and multiple mechanisms of LCn-3PUFA or clinical disease. Mechanisms of action must be better understood and RCT design and analysis improved to resolve apparent contradictory effects of LCn-3 PUFA supplements and eating fish.

**Funding source(s):** N/A.

## DAILY VS. WEEKLY ADMINISTRATION OF FISH OIL: BIOAVAILABILITY AND EFFICIENCY OF DIETARY LONG CHAIN OMEGA-3 FATTY ACIDS

S. Ghasemifard<sup>1</sup>, A.J. Sinclair<sup>1</sup>, P. Lewandowski<sup>1</sup>, G.M. Turchini<sup>2</sup>. <sup>1</sup>School of Medicine, Deakin University, VIC, Australia; <sup>2</sup>School of Life and Environmental Sciences, Deakin University, VIC, Australia  
E-mail address: [samane.ghasemifard@gmail.com](mailto:samane.ghasemifard@gmail.com) (S. Ghasemifard)

**Background/Aims:** The recommendations on the intake of long chain omega-3 polyunsaturated fatty acids (*n-3* LC-PUFA) vary from eating oily fish ('once to twice/week') to consuming specified daily amounts of EPA and DHA ('250–500 mg/day'). It is not known if there is a difference in the uptake/bioavailability between these two feeding strategies. In this study, the bioavailability of a daily dose of *n-3* LC-PUFA (Constant treatment) versus a large weekly dose of *n-3* LC-PUFA (Spike treatment) was assessed.

**Methods:** Six-week old male Sprague-Dawley rats were fed either a Constant, a Spike or Control treatment (no *n-3* LC-PUFA), for six weeks. The whole body, tissues and collected faeces were analysed for fatty acid content.

**Results:** The results showed that the major metabolic fate of the *n-3* LC-PUFA was towards catabolism ( $\beta$ -oxidation) accounting for over 70% of total dietary intake, whereas deposition accounted less than 25% of total dietary intake. It was found that significantly more *n-3* LC-PUFA were  $\beta$ -oxidised when originating from the Constant treatment (84% of dose), compared with the Spike treatment (75% of dose). Conversely, it was found that significantly more *n-3* LC-PUFA were deposited when originating from the Spike treatment (23% of dose), than from the Constant treatment (15%